Related Experiment Videos
[Remodeling of the left ventricle]
1Divisione di Cardiologia, Fondazione Salvatore Maugeri, Clinica del Lavoro e della Riabilitazione, IRCCS, Veruno.
Insights
Left ventricular remodeling, a common issue in heart conditions, can be managed. Therapies like ACE-inhibitors and beta-blockers may help, alongside moderate exercise, to improve heart function and reduce risks.
Area of Science:
- Cardiology
- Cardiovascular Research
Background:
- Left ventricular remodeling is a common, detrimental process in ischemic and non-ischemic dilated cardiomyopathy.
- It leads to reduced left ventricular systolic and diastolic performance, altering heart morphology and volume.
Purpose of the Study:
- To review therapeutic options for managing left ventricular remodeling.
- To assess the impact of medications and exercise on cardiac function and patient outcomes.
Main Methods:
- Review of current pharmacological treatments, including ACE-inhibitors, angiotensin II antagonists, and beta-blockers (metoprolol, carvedilol).
- Evaluation of the role of moderate exercise training in patients with cardiac dysfunction.
Main Results:
- ACE-inhibitors and angiotensin II antagonists may slow remodeling progression.
- Beta-blockers like metoprolol and carvedilol show potential to reverse remodeling.
- Moderate exercise training does not worsen cardiac parameters and can prevent further dysfunction.
Conclusions:
- Therapeutic interventions can positively influence left ventricular remodeling.
- Pharmacological treatments and exercise offer strategies to improve outcomes in patients with cardiomyopathy.
Abstract:
Left ventricular remodeling is a frequent and unfavorable evolution of both ischemic and non-ischemic dilative cardiomyopathy with a significant reduction in left ventricular systolic and diastolic performance. By the term "remodeling" we refer to a variety of alterations in left ventricular morphology and volume; while patients with non-ischemic cardiomyopathy frequently show global and quite homogeneous enlargement of the left ventricle, transmural myocardial infarctions can be followed initially by regional expansion and only in a second stage by a global increase in ventricular size. Cardiologists have a number of therapeutic options from which to choose: ACE-inhibitors and probably angiotensin II antagonists can contrast the unfavorable progression of the phenomenon, while beta-blockers such as metoprolol and carvedilol probably can reverse the process. In addition, moderate exercise training not only produces no detrimental effects on infarct size or left ventricular topography, but can prevent the progression of left ventricular dysfunction and its attendant morbidity and mortality in selected populations.